Background: In bifurcations, 2-stent strategy is usually associated with higher restenosis rate than a 1-stent strategy (provisional stenting). Methods: 15 ovine coronary bifurcations received main vessel Cypher stents and then were allocated to group T (nϭ8; T-stenting of the side branch with Cypher) or group P (nϭ7; PTCA of the side branch). At 180 days, the proximal, carina and distal segments of the bifurcation underwent radiographic and histologic evaluation. Results: All morphometric and qualitative data were comparable between groups at the proximal and distal sections. At the carina section, group T showed a significantly greater degree of neointimal growth (5.06Ϯ1.42 mm2 versus 2.21Ϯ0.69 mm2, pϽ0.001) and percent area stenosis (51.4Ϯ13.3% versus 31.1Ϯ7.2%, pϭ0.004) compared with group P. Both inflammation score (1.14Ϯ0.48 versus 0.36Ϯ0.38, pϭ0.005) and fibrin deposition (14.66Ϯ8.17% versus 0.79Ϯ2.10%, pϽ0.001) were significantly higher in group T. Granulomas and giant cells were observed in group T but absent in group P. Stent fracture was more prevalent (87.5% vs. 28.6%, pϽ0.05) and severe (multiple fracture: 87.5% vs. 14.3%, pϭ0.01; major fracture: 62.5% vs. 0%, pϽ0.05) in group T than group P, mostly involving the connectors at the side branches. Neointimal eccentricity was insignificantly higher in group T than group P (0.94Ϯ0.06 versus 0.89Ϯ0.12, pϭ0.45). Conclusions: Compared with balloon angioplasty, side branch T-stenting induced more neointimal growth which was likely related to higher incidence of fractures, persistent inflammation and fibrin deposition.
Background: Coronary bifurcations are frequently encountered in contemporary interventional practice and clinical outcomes are in general inferior when compared to non-bifurcation lesions. Therefore, our aim was to study the short and long-term safety and performance of the Nobori® drug-eluting stent in this lesion subset. Methods: NOBORI 2 and eNOBORI are two large, prospective, single-arm, multi-centre registries that enrolled 3067 and 7750 patients respectively, out of which 728 and 616 had at least 1 bifurcation lesion treated (BFL). In NOBORI 2, all bifurcations were included and all adverse events were adjudicated by an independent clinical event committee, while in eNOBORI, only true bifurcations were considered and adjudication is ongoing (including stent thrombosis). The primary endpoint was Target Lesion Failure (TLF) defined as composite of cardiac death (CD), target vessel related myocardial infarction (TV-MI) and target lesion revascularization (TLR). We report short and long term results of patients with BFL compared to patients without BFL treated (NBFL). Results: In the BFL group, the number of treated lesions was higher (2.4Ϯ1.5 vs 2.0Ϯ1.6; pϽ0.001), more complex (B2/C: 73% vs 54%; pϽ0.001) and more frequently ostial (21.1% vs 11.1%; pϽ0.001) and located in the LAD (55.0% vs 43.6%) and LM (5.1% vs 1.6%) than in NBFL group. TV-MI (2.1% vs 0.3%) and TLF (2.5% vs 0.7%) rates were higher in the BFL group at 1 month follow-up. In the cohort followed-up to 3-year, TV-MI (3.2% vs 2.1%) and TLR (4.4% vs 3.1%), results remained similar between the groups while cardiac death rate was significantly lower in BFL group (0.8% vs 2.7%, pϽ0.01). TLF was comparable at 3-year (6.7% vs 6.4%), with a very low number of definite and probable stent thrombosis in both subgroups (0.7% vs 0.9%). Conclusions: Good short and long-term clinical outcomes with a low rate of TLF and stent thrombosis indicate that Nobori® Biolimus A9 eluting stent, with its specific open cell design and biodegradable polymer, is safe and highly effective for the treatment of challenging bifurcation lesions, despite their complexity and frequent localization in left main coronary artery.
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